Nureca appoints Chander Kant as CFO after Naresh Gupta resigns

1 min read Updated on 30 May 2026, 03:55 AM

Reviewed by

Naman SScanX News Team

AI Summary

Nureca Limited disclosed the appointment of Chander Kant as CFO effective June 27, 2026, succeeding Naresh Gupta who resigned effective June 26, 2026. The company updated the list of authorized Key Managerial Personnel for determining materiality and making disclosures to stock exchanges.

*this image is generated using AI for illustrative purposes only.

Nureca Limited has appointed Chander Kant as the Chief Financial Officer (CFO) effective June 27, 2026, following the resignation of Mr. Naresh Gupta. The change in leadership was disclosed to the stock exchanges on May 29, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Naresh Gupta resigned from the position of CFO effective the close of business hours on June 26, 2026. Consequently, Mr. Chander Kant has been authorized to determine materiality of events and make disclosures to stock exchanges from the date of his appointment.

The company has identified Mr. Saurabh Goyal, Chairman & Managing Director, Mr. Aryan Goyal, Whole-time Director & Chief Executive Officer, and Ms. Nishu Kansal, Company Secretary & Compliance Officer, as the other Key Managerial Personnel authorized for materiality determinations. The correspondence regarding these changes was signed by Ms. Nishu Kansal on May 29, 2026. The company operates from its correspondence office in Chandigarh and its registered office in Mumbai.

The following table summarizes the key leadership changes:

Name	Role	Action	Effective Date
Naresh Gupta	Chief Financial Officer	Resignation	June 26, 2026
Chander Kant	Chief Financial Officer	Appointment	June 27, 2026

Historical Stock Returns for Nureca

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.02%	-14.57%	-12.76%	-22.45%	-16.99%	-84.77%

What strategic shifts might Nureca pursue under Chander Kant's financial leadership?

How will the market react to the sudden CFO transition in terms of stock performance?

Could this leadership change signal broader restructuring within Nureca's management?

Read Next Article

Nureca deposits INR 57.12 lakh for DRI hearing

1 min read Updated on 25 May 2026, 05:54 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

AI Summary

Nureca Limited attended a DRI hearing on May 13, 2026, concerning product classification under Section 108 of the Customs Act, 1962. The company made a pre-deposit of INR 57,12,811 without prejudice to its rights. No formal order has been issued yet.

*this image is generated using AI for illustrative purposes only.

Nureca Limited has informed the stock exchanges regarding a hearing notice received from the Directorate of Revenue Intelligence (DRI). The notice pertained to a matter concerning product classification under Section 108 of the Customs Act, 1962.

The company reported that the hearing was conducted on May 13, 2026. Nureca duly attended the proceedings and represented its case before the concerned authority during the session.

Following the hearing, the company made a pre-deposit amounting to INR 57,12,811. This payment was made pursuant to the ongoing proceedings and in accordance with applicable legal requirements. The company explicitly stated that the deposit was made without prejudice to its rights and contentions and does not constitute any admission of liability.

As of the date of the intimation, no formal order has been issued by the DRI regarding the matter. Nureca confirmed that it will keep the stock exchanges informed regarding any further material developments, including the receipt or finalization of any order, as and when required.

Key Details	Information
Regulation	Regulation 30 of SEBI (LODR) Regulations, 2015
Authority	Directorate of Revenue Intelligence (DRI)
Hearing Date	May 13, 2026
Pre-deposit Amount	INR 57,12,811
Legal Section	Section 108 of the Customs Act, 1962

Historical Stock Returns for Nureca

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.02%	-14.57%	-12.76%	-22.45%	-16.99%	-84.77%

If the DRI rules against Nureca's product classification argument, what is the potential total customs duty liability the company could face beyond the pre-deposit amount?

How might an adverse DRI order impact Nureca's import costs and pricing strategy for its health and wellness product portfolio going forward?

Could this customs classification dispute signal broader regulatory scrutiny of product categorization practices across the healthcare devices and wellness industry in India?